Myocardial toxic effects during recombinant interleukin-2 therapy.
Arterial and pulmonary artery catheters were used to monitor the cardiopulmonary effects of recombinant interleukin-2 (rIL-2) given iv at a dose of 100,000 U/kg every 8 hours on days 1-5 to 10 patients with metastatic solid tumors. As anticipated, a severe capillary leak syndrome developed in all patients. Myocardial infarction (MI) occurred unexpectedly in three patients, as evidenced by a focal injury pattern on ECG and elevations of creatinine phosphokinase myocardial band fractions. All patients receiving rIL-2 exhibited major reductions in their left ventricular stroke work index (47 +/- 11 g.m/m2 to 29 +/- g.m/m2), an index of cardiac contractility. It remains uncertain whether the MIs were a byproduct of the capillary leak syndrome in patients with underlying coronary artery disease or whether rIL-2 directly or indirectly damages cardiac muscle.
Nora
R
R
Department of Medicine, University of Maryland Cancer Center, Baltimore 21201.
Abrams
J S
JS
Tait
N S
NS
Hiponia
D J
DJ
Silverman
H J
HJ
D000328:Adult; D000368:Aged; D005260:Female; D006321:Heart / Q000187:drug effects*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007376:Interleukin-2 / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000139:chemically induced; D009369:Neoplasms / Q000188:drug therapy; D011994:Recombinant Proteins / Q000009:adverse effects
D007376:Interleukin-2; D011994:Recombinant Proteins